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Background: Diabetes mellitus (DM) accelerates plaque progression despite the use of statin therapy. The purpose
of the present study was to evaluate the determinants of atheroma progression in statin-treated patients with DM.
Methods: Coronary atherosclerosis in nonculprit lesions in a vessel undergoing percutaneous coronary intervention
(PCI) was evaluated using virtual histology intravascular ultrasound. The study included 50 patients with DM who
had been taking statin therapy for 8 months at the time of PCI.
Results: Twenty-six patients (52%) showed atheroma progression (progressors) and the remaining 24 patients (48%)
showed atheroma regression (regressors) after 8 months of follow-up. Fewer progressors than regressors received
intensive lipid-lowering therapy with pitavastatin (31% vs. 50%, p = 0.17) and the frequency of insulin use was
higher in progressors (31% vs. 13%, p = 0.18). However, neither of these differences reached statistical significance.
Risk factor control at baseline and at the 8-month follow-up did not differ between the 2 groups except for serum
levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). Univariate regression analysis showed that
serum EPA (r = −0.317, p = 0.03) and DHA (r = −0.353, p = 0.02) negatively correlated with
atheroma progression. Multivariate stepwise regression analysis showed that low serum DHA and pravastatin use
were significant independent predictors for atheroma progression during statin therapy (DHA: β = −0.414, type of
statin: β = −0.287, p = 0.001).
Conclusions: Low serum DHA is associated with progression of coronary atherosclerosis in statin-treated patients
with DM.
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Patients with diabetes mellitus (DM) are at high risk for
developing coronary artery disease (CAD) [1]. Recent
clinical trials using grayscale intravascular ultrasound
(IVUS) have shown that intensive lipid-lowering therapy
with statins results in the regression of coronary artery
plaques [2] and reduces the risk of coronary events [3,4].
However, cardiovascular events have not been reduced
by statin therapy in patients with DM [5]. Furthermore,
patients with DM have significantly more coronary
events compared to those without DM who are receiving
statin therapy [6]. This occurs because DM accelerates
plaque progression despite the use of statin therapy
[7-9]. In view of this evidence, it is important to identify
factors that are associated with plaque progression des-
pite the use of statin therapy, particularly in patients
with DM. Therefore, in this study, we evaluated the




Our study is a post-hoc subanalysis of the Treatment
with Statin on Atheroma Regression Evaluated by IVUS
with Virtual Histology (TRUTH) study. The TRUTH
study was a prospective, open-labeled, randomized, mul-
ticenter trial performed at 11 Japanese centers to evalu-
ate the effect of 8 months of treatment with pitavastatin
versus pravastatin on coronary atherosclerosis using
virtual histology (VH)-IVUS [10]. In brief, 164 patients
with angina pectoris were randomized to either pitavastatin
(4 mg/day, intensive lipid-lowering therapy) or pravastatin
(20 mg/day, moderate lipid-lowering therapy) after suc-
cessful percutaneous coronary intervention (PCI) under
VH-IVUS guidance. Follow-up IVUS examination was
performed after 8 months of statin therapy.
The inclusion criteria were having DM and analyzable
IVUS data obtained at the time of PCI and at the 8-month
follow-up. Diagnosis of DM was defined as follows: (1)
fasting plasma glucose level ≥ 126 mg/dl, and/or (2)
random plasma glucose level ≥ 200 mg/dl, and/or (3)
hemoglobin A1c (HbA1c) level ≥ 6.5%, and/or (4) treat-
ment with either oral hypoglycemic agents or insulin [11].
Of the original 164 study patients, 114 did not meet inclu-
sion criteria, leaving 50 patients who were ultimately
included in the study. These patients were divided into 2
groups: progressors and regressors. A progressor was
defined as a patient whose change in plaque volume
between the 8-month follow-up and baseline was ≥0.
A regressors was defined as a patient whose change
in plaque volume between the 8-month follow-up and
baseline was <0.
Using data from the TRUTH trial, we compared the
clinical characteristics, risk factor control, and grayscaleand VH-IVUS parameters between the progressors and
regressors. The TRUTH trial was conducted in accord-
ance with the Declaration of Helsinki and with the
approval of the institutional ethical committees of the 11
participating institutions. Each patient enrolled in this
study provided written informed consent.IVUS examination and analysis
The details of the IVUS procedure and examination
are documented [10]. In brief, after PCI of the culprit
lesion, IVUS examination was performed on angio-
graphic lesions with <50% lumen narrowing on both
the distal and proximal sides of the culprit lesion. An
Eagle Eye Gold IVUS catheter (Volcano Corporation, San
Diego, California) was used with a motorized pullback
device to withdraw the transducer at 0.5 mm/s. During
pullback, grayscale IVUS was recorded, and raw radiofre-
quency data were captured at the top of the R-wave by
using a commercially available IVUS console (IVG3;
Volcano Corporation). After 8 months of statin therapy,
the IVUS examination was repeated in the same coronary
artery using the same type of IVUS catheter used at
baseline.
All baseline and follow-up IVUS core laboratory analyses
were performed by an independent and experienced inves-
tigator (M. T.) in a blinded manner. Before IVUS analysis,
baseline and follow-up IVUS images were reviewed side-
by-side on a display, and the distal and proximal ends of
the target segment were identified by reproducible ana-
tomic landmarks such as the side-branch, vein, and stent
edge. Plaques close to the PCI site (within 5 mm) were
excluded. Manual contour detection of both the lumen
and the external elastic membrane (EEM) was performed
for each frame. Quantitative IVUS grayscale analysis was
performed according to the guidelines of the American
College of Cardiology and European Society of Cardiology
[12]. All volumetric data were divided by lesion length to
obtain a volume index. VH-IVUS data analysis was based
on grayscale border contour calculation, and relative and
absolute amounts of different coronary artery plaque com-
ponents were measured by using IVUSLab version 2.2
(Volcano Corporation).Laboratory determinations
Blood examinations for lipid levels were performed at
baseline and at the 8-month follow-up. Levels of serum
lipids, apolipoproteins, and high-sensitivity C-reactive
protein (hs-CRP) were measured at a central clinical
laboratory (SRL, Inc., Tokyo). The serum levels of ei-
cosapentaenoic acid (EPA), docosahexaenoic acid (DHA),
and arachidonic acid (AA) at baseline and at the 8-month
follow-up were measured by a central laboratory (BML,
Inc., Kawagoe).
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Statistical analyses were performed by using StatView
version 5.0 (SAS Institute, Cary, North Carolina). The
results were expressed as mean ± SD. Differences in con-
tinuous variables between the 2 groups were compared
by using an unpaired t-test when the variables showed a
normal distribution and the Mann–Whitney U-test
when the variables were not normally distributed. Differ-
ences in continuous variables within each group were
compared by using paired t-tests when the variables
showed a normal distribution and Wilcoxon’s signed-rank
sum test when the variables were not normally distributed.
Categorical variables between the 2 groups were com-
pared by using the chi-square test or Fisher’s exact test.
Univariate regression analysis was performed to determine
the predictors of atheroma progression during statin
therapy. Multivariate stepwise regression analysis was
performed among variables with a p value < 0.2 in univari-
ate analysis (hypertension, high-density lipoprotein chol-
esterol, apolipoprotein AI and B, EPA, DHA, and AA).
Statistical significance was set at p < 0.05.Table 1 Baseline characteristics of subjects
Progressors (n=26)
Age (years) 69 ± 10
Men 22 (85%)
Body mass index (kg/m2) 24.3 ± 2.5
eGFR (ml/min/1.73m2) 63.4 ± 14.1
Hypertension 21 (81%)
Smoker 8 (31%)
Pitavastatin/Pravastatin 8 (31%)/18 (69%)
Stable AP/Unstable AP 18 (69%)/8 (31%)
Target coronary artery
Left anterior descending 12 (46%)
Left circumflex 1 (4%)
Right 13 (50%)
Types of stent
Bare metal stent 3 (12%)




ACE inhibitors or ARBs 17 (65%)
β Blockers 1 (4%)
Calcium channel blockers 16 (62%)
Insulin 8 (31%)
Thiazolidine 3 (12%)
Follow-up duration (days) 236 ± 32
Data are expressed as the mean ± SD or as number (%).
eGFR, estimated glomerular filtration rate; AP, angina pectoris; ACE, angiotensin-conResults
Patient characteristics and risk factor control
Baseline characteristics of subjects are listed in Table 1.
Twenty-six patients (52%) were included in the progres-
sor group, and the remaining 24 (48%) were included in
the regressor group. There were no significant differ-
ences in baseline characteristics between the 2 groups.
Fewer progressors than regressors received intensive
lipid-lowering therapy with pitavastatin (31% vs. 50%,
p = 0.17) and the frequency of insulin use was higher
in progressors (31% vs. 13%, p = 0.18). However, neither of
these differences reached statistically significant.
Risk factor control at baseline and at the 8-month
follow-up is listed in Table 2. Serum levels of total
cholesterol, low-density lipoprotein cholesterol (LDL-C),
triglycerides, high-density lipoprotein cholesterol, hs-
CRP, oxidized LDL, lipoprotein(a), and small dense LDL
at baseline and at the 8-month follow-up did not differ
between the 2 groups. Furthermore, there were no
significant differences in plasma glucose and HbA1c
levels between the 2 groups. However, serum levels ofRegressors (n=24) p value
66 ± 10 0.28
17 (71%) 0.31
26.5 ± 4.8 0.06
63.7 ± 15.9 0.94
14 (58%) 0.12
3 (13%) 0.28
12 (50%)/12 (50%) 0.17















231 ± 28 0.58
verting enzyme; ARB, angiotensin receptor blocker.
Table 2 Risk factor control at baseline and at follow-up
At baseline At 8-month follow-up
Progressors (n=26) Regressors (n=24) p value Progressors (n=26) Regressors (n=24) p value
TC (mg/dl) 203 ± 44 218 ± 31 0.18 153 ± 31**** 165 ± 22*** 0.12
LDL-C (mg/dl) 133 ± 36 140 ± 29 0.49 85 ± 27**** 88 ± 21*** 0.67
Triglycerides (mg/dl) 127 ± 55 157 ± 96 0.18 114 ± 53 141 ± 85 0.18
HDL-C (mg/dl) 44 ± 9 46 ± 9 0.6 46 ± 11 51 ± 11* 0.1
Apolipoprotein AI (mg/dl) 114 ± 19 117 ± 16 0.55 122 ± 25 134 ± 25** 0.1
Apolipoprotein B (mg/dl) 102 ± 25 114 ± 21 0.08 70 ± 19**** 79 ± 15**** 0.1
Hs-CRP (ng/ml) 7023 ± 14355 7298 ± 9171 0.94 2856 ± 5923 2853 ± 5630* 0.99
Oxidized LDL (U/ml) 9 ± 4 12 ± 10 0.18 8 ± 3 9 ± 4* 0.6
Lipoprotein(a) (mg/dl) 16 ± 13 18 ± 14 0.63 19 ± 18 24 ± 28 0.46
Small dense LDL (mg/dl) 26 ± 16 31 ± 16 0.32 18 ± 10*** 21 ± 11* 0.32
EPA (μg/ml) 53.5 ± 28.2 71.9 ±39.2 0.08 54.9 ± 22.9 74.8 ± 36.6 0.03
DHA (μg/ml) 117.2 ± 38.3 149.3 ± 62.8 0.04 105.1 ± 31.8 135.9 ± 50.1 0.02
AA (μg/ml) 128.4 ± 35.7 144.2 ± 30.3 0.12 133.2 ± 38.2 155.8 ± 41.9 0.07
EPA/AA 0.43 ± 0.20 0.52 ± 0.34 0.26 0.44 ± 0.22 0.53 ± 0.35 0.33
DHA/AA 0.94 ± 0.28 1.04 ± 0.32 0.23 0.83 ± 0.30* 0.90 ± 0.29* 0.47
EPA + DHA/AA 1.36 ± 0.46 1.57 ± 0.58 0.19 1.28 ± 0.50 1.43 ± 0.56 0.34
Glucose (mg/dl) 135 ± 56 123 ± 39 0.44 122 ± 34 124 ± 48 0.85
HbA1c (%) 7.2 ± 1.0 7.0 ± 0.8 0.38 6.9 ± 0.9 7.0 ± 0.6 0.77
Systolic blood pressure (mmHg) 136 ± 17 134 ± 23 0.83 134 ± 20 133 ± 23 0.88
Diastolic blood pressure (mmHg) 76 ± 12 75 ± 12 0.75 73 ± 13 75 ± 12 0.56
Heart rate (beats/min) 71 ± 12 71 ± 11 0.98 72 ± 11 70 ± 15 0.5
Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with value at baseline.
TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; Hs-CRP, high-sensitivity C-reactive protein; EPA,
eicosapentaenoic acid; DHA, docosahexaenoic acid; AA, arachidonic acid; HbA1c, hemoglobin A1c.
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cantly lower in progressors than in regressors. Serum
AA levels also tended to be lower in progressors but the
difference did not reach statistical significance. EPA/AA,
DHA/AA, and EPA+DHA/AA ratios did not differ
between the 2 groups.
Grayscale and VH-IVUS analysis
The parameters evaluated by using grayscale and VH-
IVUS are shown in Table 3. There were significant
differences in percentage change of EEM volume index
(progressors: 0.2% vs. regressors: -2.7%, p = 0.01) and
lumen volume index (progressors: -6.6% vs. regressors:
2.4%, p = 0.0002) between the 2 groups. Furthermore,
necrotic core (progressors: 1.01 mm3/mm vs. regressors:
0.54 mm3/mm, p = 0.005) and dense calcium (progressors:
0.64 mm3/mm vs. regressors: 0.34 mm3/mm, p = 0.02)
plaque volume at baseline were significantly greater in
progressors than in regressors.
Predictor of atheroma progression during statin therapy
Univariate regression analysis showed that serum EPA
(r = −0.317, p = 0.03) and DHA (r = −0.353, p = 0.02)negatively correlated with atheroma progression during
statin therapy and presence of hypertension (r = 0.245,
p = 0.09) and serum AA (r = −0.277, p = 0.07) trended
in that direction (Table 4). Multivariate stepwise regres-
sion analysis showed that low serum DHA and pravastatin
use were significant independent predictors of atheroma
progression during statin therapy (DHA: β = −0.414, type
of statin: β = −0.287, p = 0.001; Table 5).
Discussion
The main findings of our study are: (1) low serum DHA
and pravastatin use were associated with atheroma pro-
gression in statin-treated patients with DM; (2) plasma
glucose and HbA1c levels did not correlate with plaque
progression or regression during statin therapy; and
(3) volume of the necrotic core component at base-
line was associated with atheroma progression during
statin therapy.
Residual risk of cardiovascular events during statin therapy
DM is accompanied by extensive atherosclerosis de-
position despite the use of medications [8], and statins
are significantly less effective at inducing regression of
Table 3 Parameters evaluated by using grayscale and virtual histology intravascular ultrasound
At baseline At 8-month follow-up
Progressors (n=26) Regressors (n=24) p value Progressors (n=26) Regressors (n=24) p value
EEM volume index (mm3/mm) 16.97 ± 5.65 16.47 ± 6.17 0.77 17.01 ± 5.80 16.03 ± 6.04*** 0.56
% change 0.2 ± 4.5 -2.7 ± 3.0 0.01
Plaque volume index (mm3/mm) 9.59 ± 3.84 9.48 ± 4.06 0.93 10.11 ± 3.86**** 8.83 ± 3.61*** 0.23
% change 6.3 ± 5.9 -6.4 ± 4.5 <0.0001
Lumen volume index (mm3/mm) 7.38 ± 2.82 6.99 ± 2.37 0.6 6.89 ± 2.69** 7.20 ± 2.73 0.69
% change -6.6 ± 9.0 2.4 ± 6.8 0.0002
Percent atheroma volume (%) 56.2 ± 8.6 57.0 ± 6.1 0.69 59.3 ± 7.8**** 54.9 ± 6.4*** 0.03
Nominal change (%) 3.2 ± 2.8 -2.2 ± 2.4 <0.0001
Fibrous volume index (mm3/mm) 3.52 ± 2.29 3.72 ± 2.18 0.75 3.92 ± 1.98* 3.11 ± 1.80**** 0.14
Change (mm3/mm) 0.40 ± 0.85 -0.61 ± 0.53 <0.0001
Fibrofatty volume index (mm3/mm) 1.08 ± 0.77 1.42 ± 1.44 0.29 0.93 ± 0.84 1.06 ± 0.93 0.62
Change (mm3/mm) -0.15 ± 0.57 -0.37 ± 0.94 0.31
Necrotic core volume index (mm3/mm) 1.01 ± 0.73 0.54 ± 0.30 0.005 1.10 ± 0.69 0.74 ± 0.49* 0.04
Change (mm3/mm) 0.09 ± 0.64 0.20 ± 0.38 0.47
Dense calcium volume index (mm3/mm) 0.64 ± 0.60 0.34 ± 0.18 0.02 0.75 ± 0.61 0.48 ± 0.43 0.08
Change (mm3/mm) 0.11 ± 0.34 0.13 ± 0.35 0.77
Average length (mm) 27.5 ± 16.3 26.1 ± 13.0 0.74 27.6 ± 17.8 26.3 ± 12.7 0.77
Data are expressed as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001 compared with value at baseline.
EEM, external elastic membrane.
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patients show atheroma regression and enhanced pre-
vention of cardiovascular events while taking statin ther-
apy, particularly diabetic patients. Serum LDL-C levels
at the 8-month follow-up did not differ between the pro-
gressors and regressors, whereas low serum DHA was
associated with progression of coronary atherosclerosis
during statin therapy. On the basis of this study’s results,
the residual risk of cardiovascular events during statin
therapy can be explained in part by n-3 polyunsaturated
fatty acids (PUFAs). Indeed, highly purified EPA is very
effective in decreasing the incidence of CAD in patients
with impaired glucose metabolism [13].
Surrogate marker of PUFAs
Plasma levels of EPA and DHA have been associated
with reduced risk of sudden death [14] and fatal ische-
mic heart disease [15]. However, the parameter that is
the best surrogate marker of PUFAs for cardiovascular
events remains unclear. Several authors tended to explain
the PUFAs effects in terms of a balance between n-3 to
n-6 PUFAs, rather than the absolute amount of each
single molecule. Domei et al. reported that lower
EPA/AA ratio, but not EPA, DHA, or DHA/AA ratio,
was associated with higher incidence of cardiac events
[16]. However, a recent cohort study reported that a lower
EPA/AA ratio was associated with a greater risk of cardio-
vascular events in patients with higher hs-CRP levels, butno clear association was observed in those with lower
hs-CRP levels [17]. In addition, the other cohort
study reported that plasma EPA and DHA, but not
AA, were inversely associated with cardiovascular
events [18]. Thus, although serum EPA/AA ratio is
one of the useful markers for the risk of cardiovascular
events, this ratio does not apply to all patients. Heterogen-
eity in population characteristics, background dietary fish
consumption, and length of follow-up may each contrib-
ute to these inconsistent findings from different study
designs. The present study found a low DHA to be associ-
ated with progression of coronary atherosclerosis, indi-
cating that low DHA could be one of biomarkers for
progression of coronary atherosclerosis. Furthermore, our
results suggest that EPA and DHA may have different
effects on coronary atherosclerosis, particularly in patients
with DM. This may be because of the enhanced peroxi-
somal β-oxidation and reduced n-3 PUFAs content in
diabetic heart [19].
PUFAs and cardiovascular events
The intake of fish is associated with a lower risk of
cardiovascular disease [20,21]. Several mechanisms may
explain the favorable association between n-3 PUFAs
and cardiovascular risk. One of these mechanisms is that
n-3 PUFAs beneficially alter the cardiovascular risk
factor profile [22,23]. In experimental studies, higher n-3
PUFAs levels alter cell membrane fluidity and receptor





Coronary artery disease status 0.017 0.9
Hypertension 0.245 0.09
Smoking 0.220 0.12





Apolipoprotein AI -0.241 0.1
Apolipoprotein B -0.239 0.1
Hs-CRP 2.576 0.99
Oxidized LDL -0.080 0.6
Lipoprotein(a) -0.109 0.46











Male gender, unstable angina pectoris, hypertension, smoking, pitavastatin,
and insulin use were assigned a value of 1. Female gender, stable angina
pectoris, normotension, nonsmoking, pravastatin and no insulin use were
assigned a value of 0.
Abbreviations as in Table 2.
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bolic precursors to potent anti-inflammatory molecules
[24]. These molecular effects may underline their systemic
and cardiac benefits such as inflammatory responses,
autonomic control, vascular and cardiac hemodynamics,
endothelial function, blood lipids, and possibly thrombosisTable 5 Multivariate stepwise regression coefficients and
F values for atheroma progression during statin therapy
Step variables β SE F value
1. DHA -0.414 0.002 8.633
2. Type of statin -0.287 0.142 4.134
Multivariate stepwise regression analysis was performed using 12 variables:
hypertension, smoking, type of statin, insulin use, TC, TG, HDL-C, apolipoprotein
AI, apolipoprotein B, EPA, DHA, and AA. Hypertension, smoking, pitavastatin, and
insulin use was assigned a value of 1. Normotension, nonsmoking, pravastatin,
and no insulin use was assigned a value of 0.[24,25]. Data from intervention studies have also identified
a lower risk of cardiovascular events associated with
purified EPA (1800 mg/day) [26] as well as EPA+DHA
(1 g/day) [27]. Pharmacological differences between EPA
and DHA have become clear in recent years, but it is still
unclear as to which of these n-3 PUFAs has a strong
antiatherogenic effect. A clinical trial reported that DHA,
but not EPA, has been associated with reduced progres-
sion of coronary atherosclerosis [28]. Two additional stud-
ies reported that DHA, but not EPA, showed a significant
inverse association with intima-media thickness [29,30].
The Japan Eicosapentaenoic Acid Lipid Intervention Study
(JELIS) showed that highly purified EPA reduced nonfatal
CAD [26]. Although the JELIS study did not report the
serum DHA level during trial, the reduction of nonfatal
CAD is more likely to be mediated through EPA rather
than DHA. In the present study, high serum EPA was
associated with atheroma regression in univariate analysis,
whereas this correlation did not observe in multivariate
analysis. Therefore, our results may suggest that DHA has
a more potent antiatherogenic effect than EPA.
Plasma glucose control and cardiovascular events
Although intensive plasma glucose control with sulfonyl-
ureas or insulin does not reduce macrovascular disease
[31], pioglitazone reduces the composite of all-cause
mortality, non-fatal myocardial infarction, and stroke in
patients with DM [32]. Furthermore, pioglitazone pre-
vents progression of coronary atherosclerosis [33] and
stabilizes coronary atherosclerosis [34], suggesting that
this medication may have beneficial effect on coronary
artery plaques. Plasma glucose and HbA1c levels did not
correlate with atheroma progression or regression in this
study. This might be due to the fact that antidiabetic
medications were not fixed during the study period.
Statin therapy for secondary prevention of cardiovascular
events
Compared with moderate lipid-lowering therapy, intensive
lipid-lowering therapy with a statin provides a significantly
greater reduction of coronary events [3,4]. Indeed, atorva-
statin 80 mg significantly reduced the rate of cardiovascular
events by 25% compared with atorvastatin 10 mg in
patients with DM [35]. This indicates that intensive LDL-C
control is necessary for secondary prevention of CAD,
particularly in patients with DM. The American Heart
Association and American College of Cardiology offer an
optimal LDL-C goal of < 70 mg/dl for patients with a very
high risk of CAD [36]. In Japan, a provisional therapeutic
goal of LDL-C with statins is < 75 mg/dl in patients with
the highest risk conditions (those with higher baseline
LDL-C level, DM, or chronic kidney disease) [37]. However,
in our study, LDL-C levels at the 8-month follow-up were
85 mg/dl in progressors and 88 mg/dl in regressors. More
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produce regression of coronary atherosclerosis in patients
with DM as previously reported [38]. Serum PUFAs have
less impact on coronary atherosclerosis in patients treated
with strong statin because a greater reduction in LDL-C
mainly affects coronary atherosclerosis [39]. The results of
this study suggest that diabetic patients should be treated
with strong statin at intensive lipid-lowering dose rather
than weak statin at moderate lipid-lowering doses for
secondary prevention of CAD.
We also observed that necrotic core and calcified plaque
volume at baseline was significantly greater in progressors
than in regressors. This may reflect ongoing, irreversible
plaque progression once the disease has reached a critical
point. It may also suggest that treatment with delayed
statin therapy would potentially be a risk for atheroma
progression and lead to future cardiovascular events. The
findings from previous trial support a strategy of the early
initiation of an aggressive LDL-C lowering to prevent
death and major cardiovascular events [40].
The present study had several limitations. First, it is a
post-hoc subanalysis of the TRUTH trial. Second, diag-
nosis of DM was made by the attending physician and a
glucose tolerance test was not conducted for all potential
study subjects. Patients with only impaired glucose
tolerance or borderline diabetes were not diagnosed as
having DM. Third, antidiabetic and antihypertensive
medications were not fixed during the study period.
Changes in medications may have affected the results of
this study. Fourth, patients were not prohibited from
making lifestyle changes. Changes in PUFA composition
of the diet likely reflect changes in serum PUFA levels. Fi-
nally, the statistical power was insufficient to characterize
the determinants of atheroma progression because of the
small number of patients. For these reasons, a prospective,
randomized, multicenter study is necessary to compare
intensive versus moderate lipid-lowering statin therapy on
coronary artery plaque volume in patients with DM.
Conclusions
We found low serum DHA was associated with progres-
sion of coronary atherosclerosis in statin-treated patients
with DM. Intensive lipid-lowering therapy with strong
statin or n-3 PUFAs add on statin therapy is necessary
to produce atheroma regression for secondary preven-
tion of CAD, particularly in patients with DM.
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